

Application Ser. No.: 10/030,600
Filing Date: April 1, 2002
Examiner: Anderson Rebecca L.

Remarks

In the Office Action, the Examiner noted that claims 1, 16, 18 and 31 are pending in the application; claims 1 and 16 are allowed; and that claims 18 and 31 are rejected. By this amendment, claims 18 and 31 have been cancelled without prejudice or disclaimer of the subject matter contained therein. Thus, claims 1 and 16 are pending in the application. No new subject matter has been inserted through these amendments. All of the amendments are fully supported by the specification. The Examiner's rejections are traversed below.

Rejection Under 35 U.S.C. § 103(a)

Claims 18 and 31 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over US Patent No. 5,780,466.

However, as noted above, claims 18 and 31 have been canceled without prejudice rendering this rejection moot. Accordingly, withdrawal of rejection as to claims 18 and 31 is respectfully requested.

Allowed Subject Matter

In response to Applicants' amendment and arguments of March 9, 2005 and May 20, 2005, the Examiner has withdrawn objection to claims 1 and 16 and has indicated that claims 1 and 16 are allowed. As noted, by way of this amendment, only claims 1 and 16 are pending in this application, and therefore, early allowance of this case is respectfully requested.

Conclusions

In view of the above Remarks, it is respectfully submitted that claims 1 and 16 are now allowed and the early issuance of this case is respectfully requested. In the event the Examiner wishes to contact the undersigned regarding any matter, please call (collect if necessary) the telephone number listed below.

Application Ser. No.: 10/030,600
Filing Date: April 1, 2002
Examiner: Anderson Rebecca L.

Applicants believe there are no fees due for this Rule 111 Amendment. However, if the Examiner deems that fees are due, please charge these fees to Deposit Account No. 18-1982 for Aventis Pharmaceuticals Inc. Bridgewater, NJ. Please credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

September 22, 2005

Balaram Gupta

Balaram Gupta, Ph. D., J. D.
Registration No. 40,009
Attorney for Applicants

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
MAIL CODE: BWD-303A
Bridgewater, NJ 08807-0800
Telephone: 908-231-3364
Telefax: 908-231-2626